pazopanib

Type: Keyphrase
Name: pazopanib
First reported Jun 28 2014 - Updated Jun 28 2014 - 1 reports

Ask Fuzzy: Why does chemotherapy make hair fall out?

Question: Why does chemotherapy cause hair to fall out? Can it make it go grey?Chemotherapy used in cancer treatment affects rapidly dividing cells, which includes the tumour cells it is aimed at treating but also normal fast-dividing cells such as hair ... [Published Canberra Times - Jun 28 2014]
First reported Jun 27 2014 - Updated Jun 27 2014 - 1 reports

Active surveillance for metastatic or recurrent renal cell carcinoma - Abstract

PURPOSE: Metastatic renal cell carcinoma (mRCC) sometimes presents with an indolent course without any significant symptoms.Here, the potential impact of active surveillance (AS) on clinical outcomes in asymptomatic or minimally symptomatic mRCC patients ... [Published UroToday - Jun 27 2014]
First reported Jun 27 2014 - Updated Jun 27 2014 - 1 reports

18F-FGD-PET measures predict mRCC TKI response

medwireNews: Positron emission tomography (PET) could be used to predict the response of metastatic renal cell carcinoma (mRCC) to tyrosine kinase inhibitor (TKI) therapy within a couple of weeks of a patient beginning treatment, research suggests.Changes ... [Published MedWire News - Jun 27 2014]
First reported Jun 25 2014 - Updated Jun 25 2014 - 1 reports

Facilitating Partial Nephrectomy with Pre-Operative Pazopanib

| GRACEWhen a patient has a localized renal mass, a partial nephrectomy is the desired surgical approach because it preserves renal function. Depending on the tumor size and location, a partial nephrectomy is not always possible. In these cases, pazopanib, ... [Published BioPortfolio - Jun 25 2014]
First reported Jun 20 2014 - Updated Jun 20 2014 - 1 reports

Another Option for Late-Stage Medullary Thyroid Cancer?

A Multicenter Phase 2 Trial of Pazopanib in Metastatic and Progressive Medullary Thyroid Carcinoma: MC057HBible KC, Suman VJ, Molina JR, et al, for the Endocrine Malignancies Disease Oriented Group, Mayo Clinic Cancer Center, and the Mayo Phase 2 Con ... [Published American Journal of Public Health - Jun 20 2014]
First reported Jun 19 2014 - Updated Jun 19 2014 - 1 reports

Nivolumab Appears 'Promising' in RCC

Nicholas J. Vogelzang, MD: I'm Nick Vogelzang, Professor of Medicine, University of Nevada School of Medicine and Vice Chair of the Southwest Oncology Group Genitourinary Committee. My work is in oncology research at the Comprehensive Cancer Centers in ... [Published Diabetes Care - Jun 19 2014]
First reported Jun 18 2014 - Updated Jun 18 2014 - 1 reports

Expert Comments on Pazopanib for Soft Tissue Sarcoma

Dr. Robin Jones, a sarcoma expert at Seattle Cancer Care Alliance, explains how a historically tough disease to treat is now no longer a life-threatening disease, but in many patients, a chronic condition.Meeting the challenges of the significant morbidity, ... [Published Chemotherapy Advisor - Jun 18 2014]
First reported Jun 18 2014 - Updated Jun 18 2014 - 1 reports

Sarcoma: A Chronic Disease?

Vicki Keedy, MD, Assistant Professor of Medicine, Clinical Director, Sarcoma Program, Vanderbilt-Ingram Cancer Center, discusses pazopanib for the treatment of soft tissue sarcoma.Meeting the challenges of the significant morbidity, functional impairment, ... [Published Chemotherapy Advisor - Jun 18 2014]
First reported Jun 16 2014 - Updated Jun 16 2014 - 1 reports

Combo Scores High in Ovarian Cancer, for Now

Stanley B. Kaye, MD: Hello. I am Stan Kaye, Professor of Medical Oncology at the Royal Marsden Hospital at the University of London. Welcome to this edition of Medscape Oncology Insights on gynecologic cancer.Today we are going to be discussing presentations ... [Published American Journal of Public Health - Jun 16 2014]
First reported Jun 12 2014 - Updated Jun 12 2014 - 1 reports

Acute aortic dissection in a patient receiving multiple tyrosine kinase inhibitors for 5 years - Abstract

A 48-year-old male presented with para-aortic lymph node metastases after surgical resection of a clear cell renal cell carcinoma.After first-line treatment with interferon alpha-2b, he was started on pazopanib and lapatinib. Blood pressure was well controlled ... [Published UroToday - Jun 12 2014]
First reported Jun 12 2014 - Updated Jun 12 2014 - 1 reports

Addition of nivolumab to sunitinib or pazopanib induced response in mRCC

CHICAGO — The PD-1 immune checkpoint inhibitor antibody nivolumab in combination with either sunitinib or pazopanib yielded encouraging antitumor activity with manageable toxicity in patients with metastatic renal cell carcinoma, according to study results ... [Published Orthopedics Today - Jun 12 2014]
First reported Mar 31 2014 - Updated Apr 01 2014 - 4 reports

Votrient's extended licence application ditched

GlaxoSmithKline admits it is ‘disappointed’ after abandoning its attempt to extend kidney cancer drug Votrient’s licence to take in ovarian cancer.The company has withdrawn an application to the European Medicines Agency for a variation to the marketing ... [Published BioPortfolio - Apr 01 2014]

Quotes

The primary thrust of these studies is their endpoint, but many more questions are raised. One question would be, "What is the best way going forward, given those subgroup analyses?" We tend to overinterpret those. But it is interesting. Hopefully, some future work will tease that out a little more
Original Article: NEXT ARTICLE More From BioPortfolio on "GSK Launches Sri Lanka's First Targeted Treatment For Renal Cell Cancer"
NEXT ARTICLE More From BioPortfolio on "GSK pulls Votrient in ovarian cancer, clears way for AZ's olaparib"
NEXT ARTICLE More From BioPortfolio on "Regulatory update: Votrient® (pazopanib) as maintenance therapy for advanced ovarian cancer in the EU"

More Content

All (38) | News (31) | Reports (0) | Blogs (5) | Audio/Video (0) | Fact Sheets (0) | Press Releases (1)
sort by: Date | Relevance
Forum Post: My husband has kidney cancer. [Published Macmillan Cancer Support - Jul 09 2014]
18F-FGD-PET measures predict mRCC TKI response [Published News-Medical.Net - Jun 30 2014]
Ask Fuzzy: Why does chemotherapy make hair fall... [Published Canberra Times - Jun 28 2014]
Active surveillance for metastatic or recurrent... [Published UroToday - Jun 27 2014]
18F-FGD-PET measures predict mRCC TKI response [Published MedWire News - Jun 27 2014]
Facilitating Partial Nephrectomy with Pre-Opera... [Published BioPortfolio - Jun 25 2014]
Another Option for Late-Stage Medullary Thyroid... [Published American Journal of Public Health - Jun 20 2014]
Nivolumab Appears 'Promising' in RCC [Published Diabetes Care - Jun 19 2014]
Sarcoma: A Chronic Disease? [Published Chemotherapy Advisor - Jun 18 2014]
Expert Comments on Pazopanib for Soft Tissue Sa... [Published Chemotherapy Advisor - Jun 18 2014]
Combo Scores High in Ovarian Cancer, for Now [Published American Journal of Public Health - Jun 16 2014]
Acute aortic dissection in a patient receiving ... [Published UroToday - Jun 12 2014]
Addition of nivolumab to sunitinib or pazopanib... [Published Orthopedics Today - Jun 12 2014]
Old member, new name? [Published HealthBoards - Jun 05 2014]
Bristol-Myers Squibb (BMY) Hosts Bristol-Myers ... [Published Seeking Alpha - Jun 02 2014]
GSK and Bayer strike new biotech cancer deals [Published PMLive - Jun 02 2014]
Axium Healthcare Pharmacy joins GSK oncology ne... [Published PharmaBiz - May 10 2014]
GSK Launches Sri Lanka's First Targeted Treatme... [Published BioPortfolio - May 06 2014]
Overall Survival in Renal-Cell Carcinoma with P... [Published The New England Journal of Medicine: Hematology ... - May 01 2014]
Withdrawn application: Votrient, pazopanib, Pos... [Published Withdrawn Application - Apr 25 2014]
Kidney cancer In crossover study patients and p... [Published BioPortfolio - Apr 16 2014]
EMA App Withdrawn for GSK Ovarian Cancer Drug [Published BioPortfolio - Apr 02 2014]
Results from phase III patient preference study... [Published News from Kidney Cancer Association - Apr 02 2014]
Votrient's extended licence application ditched [Published BioPortfolio - Apr 01 2014]
GSK pulls Votrient in ovarian cancer clears way... [Published BioPortfolio - Mar 31 2014]
Regulatory update Votrient pazopanib as mainte... [Published BioPortfolio - Mar 31 2014]
GSK withdraws European marketing authorization ... [Published BioPortfolio - Mar 31 2014]
Bladder cancer patient with rare genetic mutati... [Published BioPortfolio - Mar 13 2014]
Bladder cancer Pt with rare genetic mutations s... [Published BioPortfolio - Mar 13 2014]
Genomic testing links 'exceptional' drug respon... [Published BioPortfolio - Mar 13 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Old member, new name? [Published HealthBoards - Jun 05 2014]
When I was diagnosed with follicular ThyCa back in late 2005 I posted under my first and last name but after several years of inactivity I came back and found that Admin had changed my login to my first name along with a number. After several years more ...
Overall Survival in Renal-Cell Carcinoma with P... [Published The New England Journal of Medicine: Hematology ... - May 01 2014]
To the Editor: In the August 22 issue, we reported on a phase 3 trial showing the noninferiority, with respect to progression-free survival, of pazopanib versus sunitinib as first-line treatment for clear-cell, metastatic renal-cell carcinoma, as assessed ...
Withdrawn application: Votrient, pazopanib, Pos... [Published Withdrawn Application - Apr 25 2014]
Results from phase III patient preference study... [Published News from Kidney Cancer Association - Apr 02 2014]
The primary objective of this study was to assess how the tolerability and safety differences between GSK’s Votrient (pazopanib) versus Sutent (sunitinib)... 04/02/2014 ...
Can Novel-Novel Combinations Work? Deals Of The... [Published The IN VIVO Blog - Feb 07 2014]
Merck & Co. Inc.’s Feb. 5 announcement that it is collaborating with three companies to test various combinations of its investigational oncology compound MK-3475 with their drugs highlights the extent to which the big pharma is committed to building ...
1

Press Releases

sort by: Date | Relevance
TRACON Pharmaceuticals Initiates Phase 1b Study... [Published GlobeNewswire: Acquisitions News - Feb 03 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.